PSEN1/SLC20A2 double mutation causes early-onset Alzheimer's disease and primary familial brain calcification co-morbidity.


Journal

Neurogenetics
ISSN: 1364-6753
Titre abrégé: Neurogenetics
Pays: United States
ID NLM: 9709714

Informations de publication

Date de publication:
07 2023
Historique:
received: 30 04 2023
accepted: 07 06 2023
medline: 6 7 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: ppublish

Résumé

Primary familial brain calcification (PFBC; formerly Fahr's disease) and early-onset Alzheimer's disease (EOAD) may share partially overlapping pathogenic principles. Although the heterozygous loss-of-function mutation c.1523 + 1G > T in the PFBC-linked gene SLC20A2 was detected in a patient with asymmetric tremor, early-onset dementia, and brain calcifications, CSF β-amyloid parameters and FBB-PET suggested cortical β-amyloid pathology. Genetic re-analysis of exome sequences revealed the probably pathogenic missense mutation c.235G > A/p.A79T in PSEN1. The SLC20A2 mutation segregated with mild calcifications in two children younger than 30 years. We thus describe the stochastically extremely unlikely co-morbidity of genetic PFBC and genetic EOAD. The clinical syndromes pointed to additive rather than synergistic effects of the two mutations. MRI data revealed the formation of PFBC calcifications decades before the probable onset of the disease. Our report furthermore exemplifies the value of neuropsychology and amyloid PET for differential diagnosis.

Identifiants

pubmed: 37341843
doi: 10.1007/s10048-023-00723-x
pii: 10.1007/s10048-023-00723-x
pmc: PMC10319679
doi:

Substances chimiques

Sodium-Phosphate Cotransporter Proteins, Type III 0
SLC20A2 protein, human 0
PSEN1 protein, human 0
Presenilin-1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

209-213

Informations de copyright

© 2023. The Author(s).

Références

Westenberger A, Klein C (2014) The genetics of primary familial brain calcifications. Curr Neurol Neurosci Rep. https://doi.org/10.1007/s11910-014-0490-4
doi: 10.1007/s11910-014-0490-4 pubmed: 25212438
Nicolas G et al (2015) Brain calcification process and phenotypes according to age and sex: lessons from SLC20A2, PDGFB, and PDGFRB mutation carriers. Neuropsychiatr Genet, Amer J Med Genet Part B. https://doi.org/10.1002/ajmg.b.32336
doi: 10.1002/ajmg.b.32336
Nicolas G et al (2013) Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain 136(11):3395–3407. https://doi.org/10.1093/brain/awt255
doi: 10.1093/brain/awt255 pubmed: 24065723
Förstl H, Burns A, Cairns N, Luthert P, Levy R (1992) Basal ganglia mineralization in Alzheimer’s disease: a comparative study of clinical, neuroradiological and neuropathological findings. Behav Neurol 5(1):3–7. https://doi.org/10.3233/BEN-1992-5110
doi: 10.3233/BEN-1992-5110
Sellal F et al (2017) APP mutations in cerebral amyloid angiopathy with or without cortical calcifications: report of three families and a literature review. J Alzheimers Dis 56(1):37–46. https://doi.org/10.3233/JAD-160709
doi: 10.3233/JAD-160709 pubmed: 27858710
Sirkis DW, Bonham LW, Johnson TP, la Joie R, Yokoyama JS (2022) Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry 27(6):2674–2688. https://doi.org/10.1038/s41380-022-01531-9
doi: 10.1038/s41380-022-01531-9 pubmed: 35393555 pmcid: 9156414
Freischmidt A et al (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 18(5):631–636. https://doi.org/10.1038/nn.4000
doi: 10.1038/nn.4000 pubmed: 25803835
Pimentel LF, Lemos RR, Oliveira JR (2017) Phosphate transporters expression in patients with primary familial brain calcifications. J Mol Neurosci 62(3–4):276–280. https://doi.org/10.1007/s12031-017-0934-9
doi: 10.1007/s12031-017-0934-9 pubmed: 28578517
Cruts M et al (1998) Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 7(1):43–51. https://doi.org/10.1093/HMG/7.1.43
doi: 10.1093/HMG/7.1.43 pubmed: 9384602
Nicolas G, Charbonnier C, Campion D, Veltman JA (2018) Estimation of minimal disease prevalence from population genomic data: application to primary familial brain calcification. Neuropsychiatr Genet, Amer J Med Genet Part B. https://doi.org/10.1002/ajmg.b.32605
doi: 10.1002/ajmg.b.32605
Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16(1):30–42. https://doi.org/10.1038/S41582-019-0281-2
doi: 10.1038/S41582-019-0281-2 pubmed: 31827267
Iwase T et al (2021) Selective extension of cerebral vascular calcification in an autopsy case of Fahr’s syndrome associated with asymptomatic hypoparathyroidism. Neuropathology 41(5):387–395. https://doi.org/10.1111/neup.12760
doi: 10.1111/neup.12760 pubmed: 34462978
Batla A, Tai XY, Schottlaender L, Erro R, Balint B, Bhatia KP (2017) Deconstructing Fahr’s disease/syndrome of brain calcification in the era of new genes. Parkinsonism Relat Disord 37:1–10. https://doi.org/10.1016/J.PARKRELDIS.2016.12.024
doi: 10.1016/J.PARKRELDIS.2016.12.024 pubmed: 28162874

Auteurs

Sophie Hebestreit (S)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Janine Schwahn (J)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Vesile Sandikci (V)

Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Mate E Maros (ME)

Department of Neuroradiology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Department of Biomedical Informatics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Ivan Valkadinov (I)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Rüstem Yilmaz (R)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Lukas Eckrich (L)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Seyed Babak Loghmani (SB)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Hendrik Lesch (H)

Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Julian Conrad (J)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Holger Wenz (H)

Department of Neuroradiology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Anne Ebert (A)

Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

David Brenner (D)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Department of Neurology, University of Ulm, Ulm, Germany.

Jochen H Weishaupt (JH)

Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. jochen.weishaupt@medma.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH